← Back to work
Works cited by this work
70 works
Work: Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Michael D. Jensen, Donna H. Ryan, Caroline M. Apovian +16
Article20133 citationsABINon-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Giovanni Targher, Christopher D. Byrne, Amedeo Lonardo +2
Review article20163 citationsABIMechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease
Review article20042 citationsABIEuropean Association for the Study of the Liver (<scp>EASL</scp>), European Association for the Study of Diabetes (<scp>EASD</scp>) and European Association for the Study of Obesity (<scp>EASO</scp>) clinical practice recommendations for the management of non‐alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes
Anne-Laure Sberna, Benjamin Bouillet, Alexia Rouland +9
Article20172 citationsABINonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold +2
Review article20192 citationsABI